Journal
MEDICAL PRINCIPLES AND PRACTICE
Volume 30, Issue 4, Pages 301-310Publisher
KARGER
DOI: 10.1159/000513545
Keywords
Metabolomics; Personalised medicine; Precision medicine
Categories
Funding
- European Commission [654241]
- CIBERHD (CIBER de enfermedades hepaticas y respiratorias, Madrid)
- AGAUR, Generalitat de Catalunya [2017-SGR-1033]
- Ake Wiberg Foundation
- Icrea Academia
- BBSRC [BB/M027635/1, BB/J020265/1, BB/L024101/1, BB/I000771/1, BB/E025080/1] Funding Source: UKRI
Ask authors/readers for more resources
Metabolomics involves the systematic identification and quantification of metabolic products in the human body, offering novel diagnostic biomarkers and personalized treatment response evaluation. Potential applications in clinical practice include disruptive innovations in oncology and metabolic medicine. Challenges to widespread clinical use include data interpretation scalability, sample handling standardization, and e-infrastructure.
Metabolomics encompasses the systematic identification and quantification of all metabolic products in the human body. This field could provide clinicians with novel sets of diagnostic biomarkers for disease states in addition to quantifying treatment response to medications at an individualized level. This literature review aims to highlight the technology underpinning metabolic profiling, identify potential applications of metabolomics in clinical practice, and discuss the translational challenges that the field faces. We searched PubMed, MEDLINE, and EMBASE for primary and secondary research articles regarding clinical applications of metabolomics. Metabolic profiling can be performed using mass spectrometry and nuclear magnetic resonance-based techniques using a variety of biological samples. This is carried out in vivo or in vitro following careful sample collection, preparation, and analysis. The potential clinical applications constitute disruptive innovations in their respective specialities, particularly oncology and metabolic medicine. Outstanding issues currently preventing widespread clinical use are scalability of data interpretation, standardization of sample handling practice, and e-infrastructure. Routine utilization of metabolomics at a patient and population level will constitute an integral part of future healthcare provision.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available